Synthesis and structure-activity relationships of 3-aryloxindoles: A new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties

Journal of Medicinal Chemistry

Volumn 45, Issue 7, 2002, Pages 1487-1499

  Hewawasam, Piyasena ^a   Erway, Matthew ^a   Moon, Sandra L ^a   Knipe, Jay ^a   Weiner, Harvey ^a   Boissard, Christopher G ^a   Post Munson, Debra J ^a   Gao, Qi ^a   Huang, Stella ^a   Gribkoff, Valentin K ^a   Meanwell, Nicholas A ^a  

^a Department of Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CHLORO 2 HYDROXYPHENYL) 1,3 DIHYDRO 3 HYDROXY 6 (TRIFLUOROMETHYL) 2H INDOL 2 ONE; 3 (5 CHLORO 2 HYDROXYPHENYL) 1,3 DIHYDRO 6 (TRIFLUOROMETHYL) 2H INDOL 2 ONE; CALCIUM; GLUTAMIC ACID; LUBELUZOLE; NEUROPROTECTIVE AGENT; OXINDOLE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; ENANTIOMER; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; RACEMIC MIXTURE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STEREOCHEMISTRY; STROKE; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALS; CALCIUM; CEREBRAL ARTERIES; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; GLUTAMIC ACID; HIPPOCAMPUS; INDOLES; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MODELS, CHEMICAL; MODELS, MOLECULAR; NEURONS; NEUROPROTECTIVE AGENTS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; XENOPUS; XENOPUS LAEVIS;

EID: 0037187389     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0101850     Document Type: Article

References (50)

1. Incidence and occurrence of total (first-ever and recurrent) stroke
2. Antithrombotic and thrombolytic therapy for ischemic stroke
3. NMDA and Non-NMDA receptor gene expression following global brain ischemia in rats: Effect of NMDA and Non-NMDA receptor antagonists
4. Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors
5. Techniques for assessing neuroprotective drugs in vitro
6. Neuroprotection, excitotoxicity and NMDA antagonists
7. Therapeutic potential for adenosine receptor activation in ischemic brain injury
8. Neuroprotective effects of adenosine in cerebral ischemia: Window of opportunity
9. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
10. Calcium: Still center-stage in hypoxic-ischemic neuronal death
11. Calcium in ischemic cell death
12. Excitotoxic cell death
13. Pathobiology of ischaemic stroke: An integrated view
14. The pharmacology of potassium channels and their therapeutic potential
15. + channels
16. Potassium channel activator drugs: Mechanism of action, pharmacological properties, and therapeutic potential
17. Modulation of potassium channels by organic molecules
18. + channels: Pharmacologic properties, regulation, and therapeutic potential
19. Potassium channels: Molecular defects, diseases, and therapeutic opportunities
20. Varieties of calcium-activated potassium channels
21. + currents in neurones: Types, physiological roles and modulation
22. Modulators of large-conductance calcium-activated potassium (BK) channels as potential therapeutic targets
23. The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels
24. + channels
25. + channels by novel benzimidazolone
26. + channels in cerebellar granule cells
27. Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004
28. + currents in canine coronary artery smooth muscle cells by NS-004, or 1-(2′-hydroxy-5′-chlorophenyl)-5-trifluoromethyl-2 (3H)-benzimidazolone
29. Ion channel modulation by NS 1619, the putative BKCa channel opener, in vascular smooth muscle
30. NS 1619 activates BKCa channel activity in rat cortical neurones
31. + channels
32. Discovery of a novel class of BK channel openers: Enantiospecific synthesis and BK channel opening activity of 3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3 hydroxy-6-(trifluoromethyl)-2H-indol-2-one
33. A general method for the synthesis of isatins: Preparation of regiospecifically functionalized isatins from anilines
34. Reactivity and regioselectivity of magnesium phenolates towards isatins: One-step synthesis of 3-(2-hydroxyaryl)-3-hydroxyindolones
35. Asymmetric hydroxylation of enolates with N-sulfonyloxaziridines
36. mSlo, a complex mouse gene encoding "maxi" calcium-activated potassium channels
37. Cloning and expression of a human large-conductance calcium-activated potassium channel
38. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels
39. Cerestat and other NMDA antagonists in ischemic stroke
40. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo
41. Discovery of openers of large-conductance, calcium-activated potassium (maxi-K) channels: A new approach to stroke neuroprotection
42. Protein purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus
43. Electrophysiological recording from Xenopus oocytes
44. Atrophy of the ipsilateral substantia nigra following middle cerebral artery occlusion in the rat
45. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion
46. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels
47. Metabolism of methapyrilene by rat-liver homogenate